Clinical Trials on Haemophilus Influenzae Type B in Germany

Total 300 results

GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada
GlaxoSmithKline

Completed

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Germany
Novo Nordisk A/S

Completed

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) (explorer™6)

Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

France, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
Swedish Orphan Biovitrum

Completed

A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care

Haemophilia A | Haemophilia B

France, Germany, Italy, Spain, Sweden, Belgium, United Kingdom
Swedish Orphan Biovitrum

Completed

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B (PREVENT)

Haemophilia A | Haemophilia B

Germany
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Germany, Japan
Novo Nordisk A/S

Completed

Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

France, Israel, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

Healthy | Infant

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Italy, Greece, Germany, United Kingdom
Prof. Dr. Clemens Schmitt
Charite University, Berlin, Germany; Janssen-Cilag Ltd.

Active, not recruiting

Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (ImbruVeRCHOP)

Diffuse Large B Cell Lymphoma

Germany
Philogen S.p.A.

Terminated

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Novo Nordisk A/S

Active, not recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8)

Haemophilia A Without Inhibitors | Haemophilia B Without Inhibitors

Spain, United States, Korea, Republic of, United Kingdom, Australia, Lithuania, France, Turkey, India, Estonia, Russian Federation, Ukraine, Mexico, Japan, South Africa, Serbia, Canada, Croatia, Algeria, Bosnia and Herzegovina, ... and more
Novo Nordisk A/S

Completed

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Belgium, Germany, France, United Kingdom, Italy, Hungary, Austria, Sweden, Iran, Islamic Republic of, Argentina, Ireland, Poland, Portugal, Slovakia
University Hospital, Essen
Celgene

Completed

Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas (LeMLAR)

B-cell Lymphoma

Germany
Miltenyi Biomedicine GmbH

Active, not recruiting

MB-CART20.1 Lymphoma

Non-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

Germany
University Hospital Freiburg
German Federal Ministry of Education and Research; International Extranodal...

Unknown

High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma (MATRix)

Diffuse Large B-cell-lymphoma

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Germany
Novo Nordisk A/S

Completed

PROPACT: Retrospective Prophylaxis Patient Case Collection (PROPACT)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Slovakia, Spain, Argentina, Germany, Croatia, Italy, Canada, United Kingdom, Ireland, Sweden, France, United States, Czech Republic, Switzerland
German CLL Study Group
University of Cologne; MedacSchering Onkologie

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

B-cell Chronic Lymphocytic Leukemia

Germany
Novo Nordisk A/S

Completed

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Saudi Arabia, Algeria, Turkey, Germany, Poland, Netherlands, Italy, Belgium, South Africa, United Kingdom, Sweden, Austria, Portugal, France, Czech Republic, Venezuela
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
University Hospital Tuebingen
Hoffmann-La Roche

Completed

Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Primary Gastric Diffuse-Large B-Cell Lymphoma

Germany
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Completed

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

Lymphoma | Lymphoma, Non-Hodgkin | Large B Cell Diffuse Lymphoma

United States, Germany
Miltenyi Biomedicine GmbH
ICON plc

Active, not recruiting

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

B-cell Non Hodgkin Lymphoma

Germany
Hoffmann-La Roche

Completed

An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice

Lymphoma, B-Cell, Lymphoma, Follicular

Germany
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
Gilead Sciences; Novartis Pharmaceuticals

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Chronic Lymphocytic Leukemia

Germany
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
German CLL Study Group
Mundipharma Pte Ltd.; Roche Pharma AG

Completed

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
Roche Pharma AG; Celgene; Mundipharma Research GmbH & Co KG

Completed

A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia (CLL2P)

Chronic Lymphocytic Leukemia

Germany
University Hospital Muenster
Janssen-Cilag G.m.b.H

Completed

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut)

Diffuse Large B Cell Lymphoma

Germany
University of Giessen

Completed

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Marginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic Lymphomas

Germany
University Hospital Muenster
Bayer

Active, not recruiting

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP)

Diffuse Large B Cell Lymphoma

Germany
Hoffmann-La Roche

Completed

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Universität des Saarlandes
AstraZeneca; University of Leipzig; Wuerzburg University Hospital; University Hospital... and other collaborators

Recruiting

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED)

Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma

Germany
Charite University, Berlin, Germany
Deutsche Klinik fuer Diagnostik; University Hospital Carl Gustav Carus

Unknown

Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
iOMEDICO AG

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (RUBIN)

Chronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)

Germany
Jurgen Barth
Sponsor GmbH

Active, not recruiting

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas (MAINTAIN)

Non-Hodgkin's Lymphoma | Lymphocytic Lymphoma | Marginal Zone Lymphomas | Follicular Lymphomas | Immunocytomas | Mantle-Cell Lymphomas

Germany
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
University of Cologne
Novartis

Terminated

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019)

Non Hodgkin Lymphoma

Germany
Regeneron Pharmaceuticals

Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ORCHID)

Diffuse Large B-Cell Lymphoma

Austria, France, Germany, United Kingdom
Mathias Witzens-Harig
Charite University, Berlin, Germany; Ludwig-Maximilians - University of Munich and other collaborators

Unknown

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (STORM)

Diffuse Large B-Cell Lymphoma

Germany
Nordic Nanovector

Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell Lymphoma

Spain, United Kingdom, Italy, United States, Germany
German CLL Study Group
Janssen-Cilag Ltd.

Completed

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

Chronic Lymphocytic Leukemia

Germany
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany

Clinical Trials on Haemophilus Influenzae Type B in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations